Comparative Pharmacology
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus ALLERFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus ALLERFED.
ADVIL ALLERGY SINUS vs ALLERFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
None Documented
None Documented
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Category C
Category C
NSAID/Decongestant/Antihistamine Combination
Decongestant